CD34+/CD105+ cells are enriched in primitive circulating progenitors residing in the G0 phase of the cell cycle and contain all bone marrow and cord blood CD34+/CD38low/− precursors
Open Access
- 1 March 2000
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 108 (3) , 610-620
- https://doi.org/10.1046/j.1365-2141.2000.01869.x
Abstract
A subset of circulating CD34+ cells was found to express CD105 antigen. Sorting experiments showed that most granulocyte–macrophage colony‐forming units (GM‐CFU) and burst‐forming units — erythroid (BFU‐E) were retained in the CD34+/CD105− fraction, whereas rare GM‐CFU/BFU‐E were generated from CD34+/CD105+ cells. Megakaryocytic aggregates were entirely retained in the CD34+/CD105+ fraction. Neutralizing doses of an anti‐TGF‐β1 antibody demonstrated CD34+/CD105+ cells capable of colony‐forming activity without any significant effect on CD34+/CD105− cells. Cloning of secondary colonies revealed that CD34+/CD105+ cells had a significantly higher secondary cloning efficiency than CD34+/CD105− cells. CD34+/CD105+ cells had a significantly higher long‐term culture‐initiating cell (LTC‐IC) frequency than CD34+/CD105− cells. Kinetic analysis showed that 75% of CD34+/CD105+ cells consisted of DNA 2n G0Ki‐67− cells whereas 82% of CD34+/CD105− were DNA 2n G1Ki‐67+ cells, and this latter subset showed a RNA content consistently higher than CD34+/CD105+ cells. CD34+/CD105+ progenitors were CD25+, whereas CD34+/CD105− contained a small CD25+ subset. Three‐colour analysis of bone marrow and cord blood CD34+ cells demonstrated that all the CD34+/CD38low/− primitive precursors were contained in CD34+/CD105+ cells. Extensive characterization of these CD105+ precursors indicated that they have biological properties associated with primitive haematopoietic precursors.Keywords
This publication has 32 references indexed in Scilit:
- Erythropoietin Addition to Granulocyte Colony-Stimulating Factor Abrogates Life-Threatening Neutropenia and Increases Peripheral-Blood Progenitor-Cell Mobilization After Epirubicin, Paclitaxel, and Cisplatin Combination Chemotherapy: Results of a Randomized ComparisonJournal of Clinical Oncology, 1999
- Expansion of granulocyte colony–stimulating factor/chemotherapy–mobilized CD34+ hematopoietic progenitors: Role of granulocyte-macrophage colony-stimulating factor/erythropoietin hybrid protein (MEN11303) and interleukin-15Experimental Hematology, 1999
- Functional, phenotypic and molecular characterization of cytokine low‐responding circulating CD34+ haemopoietic progenitorsBritish Journal of Haematology, 1998
- Functional Differences between Subpopulations of Mobilized Peripheral Blood‐Derived CD34+Cells Expressing Different Levels of HLA‐DR, CD33, CD38 and c‐kit AntigensThe International Journal of Cell Cloning, 1997
- Purified unfractionated G‐CSF/chemotherapy mobilized CD34+ peripheral blood progenitors and not bone marrow CD34+ progenitors undergo selective erythroid differentiation in liquid culture in the presence of erythropoietin and stem cell factorBritish Journal of Haematology, 1997
- Peripheral Blood Progenitor Cell Transplantation: A Replacement for Marrow Auto‐ or AllograftsThe International Journal of Cell Cloning, 1996
- Expression of Thy-1 on human hematopoietic progenitor cells.The Journal of Experimental Medicine, 1993
- Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor beta 1 or Rb oligonucleotides.The Journal of Experimental Medicine, 1991
- Selective expression of CD45 isoforms on functional subpopulations of CD34+ hemopoietic cells from human bone marrow.The Journal of Experimental Medicine, 1990
- Lymphocyte stimulation: a rapid multiparameter analysis.Proceedings of the National Academy of Sciences, 1976